The burgeoning popularity of semaglutide , initially for diabetes , is creating significant interest within the UK , prompting a notable shift in peptide trends. Access these treatments remains a complex situation , with public healthcare system approval currently limited and specialist practices offering prescriptions at a premium . Concerns are b